Table 2 Estimation of the average and incremental cost-effectiveness ratio and stochastic analysis of its sensitivity
Cost-effectiveness analysis | ||
|---|---|---|
Strategy | Costs (US$)/effectiveness (DALY) | Cost-effectivenes (US$) |
  Rapid tests | 66,936 / 1,182 | 56.6 |
  Thick blood smears | 50,838 / 1,023 | 49.7 |
  Incremental analysis | 16,098 / 159 | 101.2 |
Sensitivity analysis | ||
|---|---|---|
 Rapid test | Cost (US$) | Effectiveness |
  Mean ± Deviation | 66,936 ± 4,293 | 1,182 ± 546 |
  Median | 95,039 | 1,536 |
  Range | 412–95,039 | 98–1,536 |
 Thick blood smears | ||
  Mean ± Deviation | 50,838 ± 3,818 | 1,023 ± 356 |
  Median | 81,362 | 1,290 |
  Range | 443–81,362 | 82–1,290 |
1000 simulations | ||
|---|---|---|
 Quadrant | Incremental cost-effectiveness | Frequency (%) |
  I (IE > 0 IC > 0) | ICER < US$ 1,200 | 700 (70) |
  I (IE > 0 IC > 0) | ICER > US$ 1,200 | 0 (0) |
  II (IE < 0 IC > 0) | Lower | 0 (0) |
  III (IE < 0 IC < 0) | ICER < US$ 1,200 | 250 (25) |
  III (IE < 0 IC < 0) | ICER > US$ 1,200 | 0 (0) |
  IV (IE > 0 IC < 0) | Higher | 50 (5) |